ABSTRACT
Osteoblasts are the principal bone-forming cells. As such, osteoblasts have enhanced demand for amino acids to sustain high rates of matrix synthesis associated with bone formation. The precise systems utilized by osteoblasts to meet these synthetic demands are not well understood. WNT signaling is known to rapidly stimulate glutamine uptake during osteoblast differentiation. Using a cell biology approach, we identified two amino acid transporters, γ(+)-LAT1 and ASCT2 (encoded by Slc7a7 and Slc1a5, respectively), as the primary transporters of glutamine in response to WNT. ASCT2 mediates the majority of glutamine uptake, whereas γ(+)-LAT1 mediates the rapid increase in glutamine uptake in response to WNT. Mechanistically, WNT signals through the canonical ß-catenin (CTNNB1)-dependent pathway to rapidly induce Slc7a7 expression. Conversely, Slc1a5 expression is regulated by the transcription factor ATF4 downstream of the mTORC1 pathway. Targeting either Slc1a5 or Slc7a7 using shRNA reduced WNT-induced glutamine uptake and prevented osteoblast differentiation. Collectively, these data highlight the critical nature of glutamine transport for WNT-induced osteoblast differentiation.This article has an associated First Person interview with the joint first authors of the paper.
Subject(s)
Glutamine , Osteogenesis , Cell Differentiation , Osteoblasts , Wnt Signaling Pathway , beta CateninABSTRACT
Osteoarthritis (OA) is the leading joint disease characterized by cartilage destruction and loss of mobility. Accumulating evidence indicates that the incidence and severity of OA increases with diabetes, implicating systemic glucose metabolism in joint health. However, a definitive link between cellular metabolism in articular cartilage and OA pathogenesis is not yet established. Here, we report that in mice surgically induced to develop knee OA through destabilization of medial meniscus (DMM), expression of the main glucose transporter Glut1 is notably reduced in joint cartilage. Inducible deletion of Glut1 specifically in the Prg4-expressing articular cartilage accelerates cartilage loss in DMM-induced OA. Conversely, forced expression of Glut1 protects against cartilage destruction following DMM. Moreover, in mice with type I diabetes, both Glut1 expression and the rate of glycolysis are diminished in the articular cartilage, and the diabetic mice exhibit more severe cartilage destruction than their nondiabetic counterparts following DMM. The results provide proof of concept that boosting glucose metabolism in articular chondrocytes may ameliorate cartilage degeneration in OA.
Subject(s)
Cartilage, Articular , Diabetes Mellitus, Experimental , Osteoarthritis , Animals , Cartilage, Articular/metabolism , Chondrocytes/metabolism , Diabetes Mellitus, Experimental/metabolism , Disease Models, Animal , Glucose/metabolism , Glucose Transporter Type 1/genetics , Glucose Transporter Type 1/metabolism , Mice , Osteoarthritis/metabolismABSTRACT
The past 15 years have witnessed tremendous progress in the molecular understanding of osteoblasts, the main bone-forming cells in the vertebrate skeleton. In particular, all of the major developmental signals (including WNT and Notch signalling), along with an increasing number of transcription factors (such as RUNX2 and osterix), have been shown to regulate the differentiation and/or function of osteoblasts. As evidence indicates that osteoblasts may also regulate the behaviour of other cell types, a clear understanding of the molecular identity and regulation of osteoblasts is important beyond the field of bone biology.
Subject(s)
Bone Development , Osteoblasts/metabolism , Animals , Bone Morphogenetic Proteins/metabolism , Cell Differentiation , Cell Lineage , Core Binding Factor alpha Subunits/metabolism , Female , Fibroblast Growth Factors/metabolism , Humans , Male , Mice , Rats , Receptors, Notch/metabolism , Signal Transduction , Transcription Factors/metabolism , Wnt Proteins/metabolismABSTRACT
Mutations in LRP5, a coreceptor for Wnt proteins, cause the disease osteoporosis pseudoglioma. A new study by Yadav et al. (2008) now challenges the view that LRP5 controls bone mass through Wnt signaling in bone and argues instead that LRP5 regulates bone mass indirectly through its effects on serotonin synthesis in the gut.
Subject(s)
Bone and Bones/metabolism , Gastrointestinal Tract/metabolism , LDL-Receptor Related Proteins/metabolism , Animals , Humans , Low Density Lipoprotein Receptor-Related Protein-5 , Osteoporosis/genetics , Osteoporosis/metabolism , Serotonin/metabolism , Wnt Proteins/metabolismABSTRACT
Canonical Wnt signaling critically regulates cell fate and proliferation in development and disease. Nuclear localization of beta-catenin is indispensable for canonical Wnt signaling; however, the mechanisms governing beta-catenin nuclear localization are not well understood. Here we demonstrate that nuclear accumulation of beta-catenin in response to Wnt requires Rac1 activation. The role of Rac1 depends on phosphorylation of beta-catenin at Ser191 and Ser605, which is mediated by JNK2 kinase. Mutations of these residues significantly affect Wnt-induced beta-catenin nuclear accumulation. Genetic ablation of Rac1 in the mouse embryonic limb bud ectoderm disrupts canonical Wnt signaling and phenocopies deletion of beta-catenin in causing severe truncations of the limb. Finally, Rac1 interacts genetically with beta-catenin and Dkk1 in controlling limb outgrowth. Together these results uncover Rac1 activation and subsequent beta-catenin phosphorylation as a hitherto uncharacterized mechanism controlling canonical Wnt signaling and may provide additional targets for therapeutic intervention of this important pathway.
Subject(s)
Cell Nucleus/chemistry , Neuropeptides/metabolism , Signal Transduction , beta Catenin/analysis , rac GTP-Binding Proteins/metabolism , Animals , Cell Line , Cell Nucleus/metabolism , Embryo, Mammalian/metabolism , Extremities/embryology , Intercellular Signaling Peptides and Proteins/metabolism , Mice , Mitogen-Activated Protein Kinase 9/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Wnt Proteins/metabolism , Wnt3 Protein , beta Catenin/genetics , beta Catenin/metabolism , rac1 GTP-Binding Protein , rho GTP-Binding Proteins/metabolismABSTRACT
The development of lipid nanoparticle (LNP) formulations for targeting the bone microenvironment holds significant potential for nucleic acid therapeutic applications including bone regeneration, cancer, and hematopoietic stem cell therapies. However, therapeutic delivery to bone remains a significant challenge due to several biological barriers, such as low blood flow in bone, blood-bone marrow barriers, and low affinity between drugs and bone minerals, which leads to unfavorable therapeutic dosages in the bone microenvironment. Here, we construct a series of bisphosphonate (BP) lipid-like materials possessing a high affinity for bone minerals, as a means to overcome biological barriers to deliver mRNA therapeutics efficiently to the bone microenvironment in vivo. Following in vitro screening of BP lipid-like materials formulated into LNPs, we identified a lead BP-LNP formulation, 490BP-C14, with enhanced mRNA expression and localization in the bone microenvironment of mice in vivo compared to 490-C14 LNPs in the absence of BPs. Moreover, BP-LNPs enhanced mRNA delivery and secretion of therapeutic bone morphogenetic protein-2 from the bone microenvironment upon intravenous administration. These results demonstrate the potential of BP-LNPs for delivery to the bone microenvironment, which could potentially be utilized for a range of mRNA therapeutic applications including regenerative medicine, protein replacement, and gene editing therapies.
Subject(s)
Lipids , Nanoparticles , Animals , Diphosphonates/pharmacology , Liposomes , Mice , RNA, Messenger/genetics , RNA, Small Interfering/geneticsABSTRACT
Glucocorticoids, widely prescribed for anti-inflammatory and immunosuppressive purposes, are the most common secondary cause for osteoporosis and related fractures. Current anti-resorptive and anabolic therapies are insufficient for treating glucocorticoid-induced osteoporosis due to contraindications or concerns of side effects. Glucocorticoids have been shown to disrupt Wnt signaling in osteoblast-lineage cells, but the efficacy for Wnt proteins to restore bone mass after glucocorticoid therapy has not been examined. Here by using two mouse genetic models wherein WNT7B expression is temporally activated by either tamoxifen or doxycycline in osteoblast-lineage cells, we show that WNT7B recovers bone mass following glucocorticoid-induced bone loss, thanks to increased osteoblast number and function. However, WNT7B overexpression in bone either before or after glucocorticoid treatments does not ameliorate the abnormal accumulation of body fat. The study demonstrates a potent bone anabolic function for WNT7B in countering glucocorticoid-induced bone loss.
Subject(s)
Bone Density , Glucocorticoids/toxicity , Osteogenesis , Osteoporosis/prevention & control , Proto-Oncogene Proteins/metabolism , Wnt Proteins/metabolism , Animals , Male , Mice , Osteoporosis/chemically induced , Osteoporosis/pathology , Proto-Oncogene Proteins/genetics , Wnt Proteins/geneticsABSTRACT
PURPOSE OF REVIEW: This review summarizes recent developments on the effects of glycemic control and diabetes on bone health. We discuss the foundational cellular mechanisms through which diabetes and impaired glucose control impact bone biology, and how these processes contribute to bone fragility in diabetes. RECENT FINDINGS: Glucose is important for osteoblast differentiation and energy consumption of mature osteoblasts. The role of insulin is less clear, but insulin receptor deletion in mouse osteoblasts reduces bone formation. Epidemiologically, type 1 (T1D) and type 2 diabetes (T2D) associate with increased fracture risk, which is greater among people with T1D. Accumulation of cortical bone micro-pores, micro-vascular complications, and AGEs likely contribute to diabetes-related bone fragility. The effects of youth-onset T2D on peak bone mass attainment and subsequent skeletal fragility are of particular concern. Further research is needed to understand the effects of hyperglycemia on skeletal health through the lifecycle, including the related factors of inflammation and microvascular damage.
Subject(s)
Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Mice , Animals , Diabetes Mellitus, Type 2/complications , Glycemic Control , Diabetes Mellitus, Type 1/complications , Bone and Bones , Bone DensityABSTRACT
Excessive bone resorption over bone formation is the root cause for bone loss leading to osteoporotic fractures. Development of new antiresorptive therapies calls for a holistic understanding of osteoclast differentiation and function. Although much has been learned about the molecular regulation of osteoclast biology, little is known about the metabolic requirement and bioenergetics during osteoclastogenesis. Here, we report that glucose metabolism through oxidative phosphorylation (OXPHOS) is the predominant bioenergetic pathway to support osteoclast differentiation. Meanwhile, increased lactate production from glucose, known as aerobic glycolysis when oxygen is abundant, is also critical for osteoclastogenesis. Genetic deletion of Glut1 in osteoclast progenitors reduces aerobic glycolysis without compromising OXPHOS, but nonetheless diminishes osteoclast differentiation in vitro. Glut1 deficiency in the progenitors leads to osteopetrosis due to fewer osteoclasts specifically in the female mice. Thus, Glut1-mediated glucose metabolism through both lactate production and OXPHOS is necessary for normal osteoclastogenesis.
Subject(s)
Cell Differentiation/physiology , Cell Respiration/physiology , Glycolysis/physiology , Mitochondria/physiology , Osteoclasts/physiology , Animals , Bone Resorption/metabolism , Bone Resorption/physiopathology , Energy Metabolism/physiology , Female , Glucose/metabolism , Glucose Transporter Type 1/metabolism , Male , Mice , Mice, Inbred C57BL , Mitochondria/metabolism , Osteoclasts/metabolism , Osteogenesis/physiology , Oxidative Phosphorylation , Oxygen/metabolismABSTRACT
Wingless/integrated (Wnt) signaling has emerged as a major mechanism for promoting bone formation and a target pathway for developing bone anabolic agents against osteoporosis. However, the downstream events mediating the potential therapeutic effect of Wnt proteins are not fully understood. Previous studies have indicated that increased glycolysis is associated with osteoblast differentiation in response to Wnt signaling, but direct genetic evidence for the importance of glucose metabolism in Wnt-induced bone formation is lacking. Here, we have generated compound transgenic mice to overexpress Wnt family member 7B (Wnt7b) transiently in the osteoblast lineage of postnatal mice, with or without concurrent deletion of the glucose transporter 1 (Glut1), also known as solute carrier family 2, facilitated glucose transporter member 1. Overexpression of Wnt7b in 1-mo-old mice for 1 wk markedly stimulated bone formation, but the effect was essentially abolished without Glut1, even though transient deletion of Glut1 itself did not affect normal bone accrual. Consistent with the in vivo results, Wnt7b increased Glut1 expression and glucose consumption in the primary culture of osteoblast lineage cells, and deletion of Glut1 diminished osteoblast differentiation in vitro. Thus, Wnt7b promotes bone formation in part through stimulating glucose metabolism in osteoblast lineage cells.-Chen, H., Ji, X., Lee, W.-C., Shi, Y., Li, B., Abel, E. D., Jiang, D., Huang, W., Long, F. Increased glycolysis mediates Wnt7b-induced bone formation.
Subject(s)
Glucose Transporter Type 1/physiology , Glucose/metabolism , Glycolysis , Osteoblasts/metabolism , Osteogenesis/physiology , Proto-Oncogene Proteins/physiology , Wnt Proteins/physiology , Animals , Cell Lineage , Cells, Cultured , Femur/growth & development , Femur/ultrastructure , Gene Expression Regulation, Developmental/drug effects , Genes, Reporter , Glucose Transporter Type 1/deficiency , Glucose Transporter Type 1/genetics , Mice , Mice, Transgenic , Osteogenesis/drug effects , Proto-Oncogene Proteins/genetics , Recombinant Proteins/metabolism , Tamoxifen/pharmacology , Tibia/growth & development , Tibia/ultrastructure , Wnt Proteins/geneticsABSTRACT
Fibroblast growth factor (FGF) signaling is important for skeletal development; however, cell-specific functions, redundancy and feedback mechanisms regulating bone growth are poorly understood. FGF receptors 1 and 2 (Fgfr1 and Fgfr2) are both expressed in the osteoprogenitor lineage. Double conditional knockout mice, in which both receptors were inactivated using an osteoprogenitor-specific Cre driver, appeared normal at birth; however, these mice showed severe postnatal growth defects that include an â¼50% reduction in body weight and bone mass, and impaired longitudinal bone growth. Histological analysis showed reduced cortical and trabecular bone, suggesting cell-autonomous functions of FGF signaling during postnatal bone formation. Surprisingly, the double conditional knockout mice also showed growth plate defects and an arrest in chondrocyte proliferation. We provide genetic evidence of a non-cell-autonomous feedback pathway regulating Fgf9, Fgf18 and Pthlh expression, which led to increased expression and signaling of Fgfr3 in growth plate chondrocytes and suppression of chondrocyte proliferation. These observations show that FGF signaling in the osteoprogenitor lineage is obligately coupled to chondrocyte proliferation and the regulation of longitudinal bone growth.
Subject(s)
Bone Development , Cell Lineage , Chondrocytes/cytology , Fibroblast Growth Factors/metabolism , Osteocytes/cytology , Signal Transduction , Stem Cells/cytology , Animals , Animals, Newborn , Bone Development/drug effects , Cell Lineage/drug effects , Cell Proliferation/drug effects , Chondrocytes/drug effects , Chondrocytes/metabolism , Growth Plate/drug effects , Growth Plate/metabolism , Integrases/metabolism , Mice, Knockout , Models, Biological , Osteocytes/drug effects , Osteocytes/metabolism , Parathyroid Hormone-Related Protein/administration & dosage , Parathyroid Hormone-Related Protein/pharmacology , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Receptor, Fibroblast Growth Factor, Type 2/metabolism , Signal Transduction/drug effects , Sp7 Transcription Factor , Stem Cells/drug effects , Stem Cells/metabolism , Transcription Factors/metabolismABSTRACT
Exogenous bone morphogenetic proteins (Bmp) are well known to induce ectopic bone formation, but the physiological effect of Bmp signaling on normal bone is not completely understood. By deleting the receptor Bmpr1a in osteoblast lineage cells with Dmp1-Cre, we observed a dramatic increase in trabecular bone mass in postnatal mice, which was due to a marked increase in osteoblast number that was likely to be driven by hyperproliferation of Sp7(+) preosteoblasts. Similarly, inducible deletion of Bmpr1a in Sp7(+) cells specifically in postnatal mice increased trabecular bone mass. However, deletion of Smad4 by the same approaches had only a minor effect, indicating that Bmpr1a signaling suppresses trabecular bone formation through effectors beyond Smad4. Besides increasing osteoblast number in the trabecular bone, deletion of Bmpr1a by Dmp1-Cre also notably reduced osteoblast activity, resulting in attenuation of periosteal bone growth. The impairment in osteoblast activity correlated with reduced mTORC1 signaling in vivo, whereas inhibition of mTORC1 activity abolished the induction of protein anabolism genes by BMP2 treatment in vitro. Thus, physiological Bmpr1a signaling in bone exerts a dual function in both restricting preosteoblast proliferation and promoting osteoblast activity.
Subject(s)
Bone Morphogenetic Protein Receptors, Type I/metabolism , Osteoblasts/cytology , Osteoblasts/metabolism , Animals , Bone Morphogenetic Protein Receptors, Type I/genetics , Cells, Cultured , Extracellular Matrix Proteins/genetics , Extracellular Matrix Proteins/metabolism , Mice , Signal Transduction/genetics , Signal Transduction/physiologyABSTRACT
Tendon attaches to bone across a specialized tissue called the enthesis. This tissue modulates the transfer of muscle forces between two materials, i.e. tendon and bone, with vastly different mechanical properties. The enthesis for many tendons consists of a mineralized graded fibrocartilage that develops postnatally, concurrent with epiphyseal mineralization. Although it is well described that the mineralization and development of functional maturity requires muscle loading, the biological factors that modulate enthesis development are poorly understood. By genetically demarcating cells expressing Gli1 in response to Hedgehog (Hh) signaling, we discovered a unique population of Hh-responsive cells in the developing murine enthesis that were distinct from tendon fibroblasts and epiphyseal chondrocytes. Lineage-tracing experiments revealed that the Gli1 lineage cells that originate in utero eventually populate the entire mature enthesis. Muscle paralysis increased the number of Hh-responsive cells in the enthesis, demonstrating that responsiveness to Hh is modulated in part by muscle loading. Ablation of the Hh-responsive cells during the first week of postnatal development resulted in a loss of mineralized fibrocartilage, with very little tissue remodeling 5 weeks after cell ablation. Conditional deletion of smoothened, a molecule necessary for responsiveness to Ihh, from the developing tendon and enthesis altered the differentiation of enthesis progenitor cells, resulting in significantly reduced fibrocartilage mineralization and decreased biomechanical function. Taken together, these results demonstrate that Hh signaling within developing enthesis fibrocartilage cells is required for enthesis formation.
Subject(s)
Fibrocartilage/cytology , Hedgehog Proteins/metabolism , Muscles/physiology , Animals , Animals, Newborn , Biomechanical Phenomena , Botulinum Toxins/toxicity , Calcification, Physiologic , Integrases/metabolism , Mice, Transgenic , Models, Biological , Paralysis/chemically induced , Paralysis/pathology , Signal Transduction , Weight-Bearing , X-Ray MicrotomographyABSTRACT
The long tendons of the limb extend from muscles that reside in the zeugopod (arm/leg) to their skeletal insertions in the autopod (paw). How these connections are established along the length of the limb remains unknown. Here, we show that mouse limb tendons are formed in modular units that combine to form a functional contiguous structure; in muscle-less limbs, tendons develop in the autopod but do not extend into the zeugopod, and in the absence of limb cartilage the zeugopod segments of tendons develop despite the absence of tendons in the autopod. Analyses of cell lineage and proliferation indicate that distinct mechanisms govern the growth of autopod and zeugopod tendon segments. To elucidate the integration of these autopod and zeugopod developmental programs, we re-examined early tendon development. At E12.5, muscles extend across the full length of a very short zeugopod and connect through short anlagen of tendon progenitors at the presumptive wrist to their respective autopod tendon segment, thereby initiating musculoskeletal integration. Zeugopod tendon segments are subsequently generated by proximal elongation of the wrist tendon anlagen, in parallel with skeletal growth, underscoring the dependence of zeugopod tendon development on muscles for tendon anchoring. Moreover, a subset of extensor tendons initially form as fused structures due to initial attachment of their respective wrist tendon anlage to multiple muscles. Subsequent individuation of these tendons depends on muscle activity. These results establish an integrated model for limb tendon development that provides a framework for future analyses of tendon and musculoskeletal phenotypes.
Subject(s)
Extremities/embryology , Gene Expression Regulation, Developmental , Muscle, Skeletal/embryology , Tendons/embryology , Animals , Apoptosis , Basic Helix-Loop-Helix Transcription Factors/genetics , Cartilage/metabolism , Cell Differentiation , Cell Lineage , Cell Proliferation , Gene Deletion , Green Fluorescent Proteins/metabolism , Metacarpophalangeal Joint/pathology , Mice , Microscopy, Confocal , Microscopy, Electron, Transmission , Muscle, Skeletal/metabolism , Phenotype , SOX9 Transcription Factor/genetics , Tendons/metabolismABSTRACT
The adult human skeleton is a multifunctional organ undergoing continuous remodeling. Homeostasis of bone mass in a healthy adult requires an exquisite balance between bone resorption by osteoclasts and bone formation by osteoblasts; disturbance of such balance is the root cause for various bone disorders including osteoporosis. To develop effective and safe therapeutics to modulate bone formation, it is essential to elucidate the molecular mechanisms governing osteoblast differentiation and activity. Due to their specialized function in collagen synthesis and secretion, osteoblasts are expected to consume large amounts of nutrients. However, studies of bioenergetics and building blocks in osteoblasts have been lagging behind those of growth factors and transcription factors. Genetic studies in both humans and mice over the past 15 years have established Wnt signaling as a critical mechanism for stimulating osteoblast differentiation and activity. Importantly, recent studies have uncovered that Wnt signaling directly reprograms cellular metabolism by stimulating aerobic glycolysis, glutamine catabolism as well as fatty acid oxidation in osteoblast-lineage cells. Such findings therefore reveal an important regulatory axis between bone anabolic signals and cellular bioenergetics. A comprehensive understanding of osteoblast metabolism and its regulation is likely to reveal molecular targets for novel bone therapies.
Subject(s)
Osteoblasts/cytology , Osteoblasts/metabolism , Signal Transduction , Wnt Proteins/metabolism , Animals , Bone and Bones/metabolism , Humans , Models, Biological , Wnt Signaling PathwayABSTRACT
Hedgehog (Hh) signaling is essential for osteoblast differentiation in the endochondral skeleton during embryogenesis. However, the molecular mechanism underlying the osteoblastogenic role of Hh is not completely understood. Here, we report that Hh markedly induces the expression of insulin-like growth factor 2 (Igf2) that activates the mTORC2-Akt signaling cascade during osteoblast differentiation. Igf2-Akt signaling, in turn, stabilizes full-length Gli2 through Serine 230, thus enhancing the output of transcriptional activation by Hh. Importantly, genetic deletion of the Igf signaling receptor Igf1r specifically in Hh-responding cells diminishes bone formation in the mouse embryo. Thus, Hh engages Igf signaling in a positive feedback mechanism to activate the osteogenic program.
Subject(s)
Cell Differentiation , Hedgehog Proteins/metabolism , Insulin-Like Growth Factor II/metabolism , Osteoblasts/metabolism , Animals , Blotting, Western , Cell Line , Feedback, Physiological/drug effects , Female , Hedgehog Proteins/agonists , Hedgehog Proteins/genetics , In Situ Hybridization , Insulin-Like Growth Factor II/genetics , Kruppel-Like Transcription Factors/genetics , Kruppel-Like Transcription Factors/metabolism , Mechanistic Target of Rapamycin Complex 2 , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/metabolism , Mice, Knockout , Mice, Transgenic , Morpholines/pharmacology , Multiprotein Complexes/genetics , Multiprotein Complexes/metabolism , Osteoblasts/cytology , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Purines/pharmacology , RNA Interference , Receptors, Somatomedin/genetics , Receptors, Somatomedin/metabolism , Recombinant Proteins/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , TOR Serine-Threonine Kinases/genetics , TOR Serine-Threonine Kinases/metabolism , Zinc Finger Protein GLI1ABSTRACT
Developmental signals in metazoans play critical roles in inducing cell differentiation from multipotent progenitors. The existing paradigm posits that the signals operate directly through their downstream transcription factors to activate expression of cell type-specific genes, which are the hallmark of cell identity. We have investigated the mechanism through which Wnt signaling induces osteoblast differentiation in an osteoblast-adipocyte bipotent progenitor cell line. Unexpectedly, Wnt3a acutely suppresses the expression of a large number of genes while inducing osteoblast differentiation. The suppressed genes include Pparg and Cebpa, which encode adipocyte-specifying transcription factors and suppression of which is sufficient to induce osteoblast differentiation. The large scale gene suppression induced by Wnt3a corresponds to a global decrease in histone acetylation, an epigenetic modification that is associated with gene activation. Mechanistically, Wnt3a does not alter histone acetyltransferase or deacetylase activities but, rather, decreases the level of acetyl-CoA in the nucleus. The Wnt-induced decrease in histone acetylation is independent of ß-catenin signaling but, rather, correlates with suppression of glucose metabolism in the tricarboxylic acid cycle. Functionally, preventing histone deacetylation by increasing nucleocytoplasmic acetyl-CoA levels impairs Wnt3a-induced osteoblast differentiation. Thus, Wnt signaling induces osteoblast differentiation in part through histone deacetylation and epigenetic suppression of an alternative cell fate.
Subject(s)
Acetyl Coenzyme A/metabolism , Cell Differentiation , Cell Nucleus/metabolism , Osteoblasts/physiology , Wnt Signaling Pathway , Wnt3A Protein/physiology , Acetylation , Animals , Cell Line , Citric Acid/metabolism , Citric Acid Cycle , Gene Expression , Gene Silencing , Glucose/metabolism , Histones/metabolism , Mice , Protein Processing, Post-TranslationalABSTRACT
mTORC1 signaling has been shown to promote limb skeletal growth through stimulation of protein synthesis in chondrocytes. However, potential roles of mTORC1 in prechondrogenic mesenchyme have not been explored. In this study, we first deleted Raptor, a unique and essential component of mTORC1, in prechondrogenic limb mesenchymal cells. Deletion of Raptor reduced the size of limb bud cells, resulting in overall diminution of the limb bud without affecting skeletal patterning. We then examined the potential role of mTORC1 in chondrogenic differentiation in vitro. Both pharmacological and genetic disruption of mTORC1 significantly suppressed the number and size of cartilage nodules in micromass cultures of limb bud mesenchymal cells. Similarly, inhibition of mTORC1 signaling in chondrogenic ATDC5 cells greatly impaired cartilage nodule formation, and decreased the expression of the master transcriptional factor Sox9, along with the cartilage matrix genes Acan and Col2a1. Thus, we have identified an important role for mTORC1 signaling in promoting limb mesenchymal cell growth and chondrogenesis during embryonic development. J. Cell. Biochem. 118: 748-753, 2017. © 2016 Wiley Periodicals, Inc.
Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Chondrogenesis/physiology , Limb Buds/embryology , Multiprotein Complexes/physiology , TOR Serine-Threonine Kinases/physiology , Adaptor Proteins, Signal Transducing/deficiency , Adaptor Proteins, Signal Transducing/genetics , Animals , Cells, Cultured , Chondrocytes/cytology , Chondrocytes/drug effects , Chondrocytes/physiology , Chondrogenesis/drug effects , Chondrogenesis/genetics , Embryonic Stem Cells/cytology , Embryonic Stem Cells/physiology , Female , Limb Buds/cytology , Limb Buds/physiology , Mechanistic Target of Rapamycin Complex 1 , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/physiology , Mice , Mice, Knockout , Multiprotein Complexes/deficiency , Multiprotein Complexes/genetics , Pregnancy , Regulatory-Associated Protein of mTOR , Signal Transduction , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/deficiency , TOR Serine-Threonine Kinases/geneticsABSTRACT
Adolescent idiopathic scoliosis (AIS) and pectus excavatum (PE) are common pediatric musculoskeletal disorders. Little is known about the tissue of origin for either condition, or about their genetic bases. Common variants near GPR126/ADGRG6 (encoding the adhesion G protein-coupled receptor 126/adhesion G protein-coupled receptor G6, hereafter referred to as GPR126) were recently shown to be associated with AIS in humans. Here, we provide genetic evidence that loss of Gpr126 in osteochondroprogenitor cells alters cartilage biology and spinal column development. Microtomographic and x-ray studies revealed several hallmarks of AIS, including postnatal onset of scoliosis without malformations of vertebral units. The mutants also displayed a dorsal-ward deflection of the sternum akin to human PE. At the cellular level, these defects were accompanied by failure of midline fusion within the developing annulus fibrosis of the intervertebral discs and increased apoptosis of chondrocytes in the ribs and vertebrae. Molecularly, we found that loss of Gpr126 upregulated the expression of Gal3st4, a gene implicated in human PE, encoding Galactose-3-O-sulfotransferase 4. Together, these data uncover Gpr126 as a genetic cause for the pathogenesis of AIS and PE in a mouse model.
Subject(s)
Funnel Chest/genetics , Receptors, G-Protein-Coupled/genetics , Scoliosis/genetics , Sulfotransferases/genetics , Animals , Cartilage , Chondrocytes/pathology , Disease Models, Animal , Funnel Chest/pathology , Genetic Predisposition to Disease , Humans , Mice , Receptors, G-Protein-Coupled/biosynthesis , Scoliosis/pathology , Sternum/pathology , Sulfotransferases/biosynthesisABSTRACT
Much of the mammalian skeleton is derived from a cartilage template that undergoes rapid growth during embryogenesis, but the molecular mechanism of growth regulation is not well understood. Signaling by mammalian target of rapamycin complex 1 (mTORC1) is an evolutionarily conserved mechanism that controls cellular growth. Here we report that mTORC1 signaling is activated during limb cartilage development in the mouse embryo. Disruption of mTORC1 signaling through deletion of either mTOR or the associated protein Raptor greatly diminishes embryonic skeletal growth associated with severe delays in chondrocyte hypertrophy and bone formation. The growth reduction of cartilage is not due to changes in chondrocyte proliferation or survival, but is caused by a reduction in cell size and in the amount of cartilage matrix. Metabolic labeling reveals a notable deficit in the rate of protein synthesis in Raptor-deficient chondrocytes. Thus, mTORC1 signaling controls limb skeletal growth through stimulation of protein synthesis in chondrocytes.